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Summsry 
The presence and the role of interleukin 10 (IL-10), a potent cytokine synthesis inhibitory factor 
and antiinflammatory cytokine, were investigated in rheumatoid arthritis (RA). The expression 
of both mRNA and protein for IL-10 could be demonstrated in RA and osteoarthritis (OA) 
joints. Human IL-10 mRNA could be demonstrated by polymerase chain reaction amplification 
of cDNA made by reverse transcription of total RNA extracted directly from synovial tissue 
in five out of five RA and four out of five OA patients. IL-10 protein was demonstrated by 
specific immunoassay and immunohistology. IL-10 protein was spontaneously produced in all 
11 RA and 17 OA synovial membrane cultures investigated, and this production was sustained 
for up to 5 d in culture in the absence of any extrinsic stimulation. IL-10 protein could also 
be detected by immunohistology  in all five RA and four OA synovial membrane  biopsies investigated, 
but not three normal synovial membranes. Immunohistology  revealed that the IL-10 was localized 
to the synovial membrane lining layer and mononuclear cell aggregates.  Immunofluorescence 
double staining revealed that the sources of IL-10 were monocytes in the lining layer, and T 
cells in the mononuclear cell aggregates.  We found evidence  that the IL-IO expression  was 
functionally relevant,  as neutralization of endogenously produced IL-10 in the RA synovial 
membrane cultures resulted in a two- to threefold increase in the protein levels of proinflammatory 
cytokines tumor necrosis factor c~ (TNF-c  0  and IL-1B,  although IL-6 and IL-8 levels were not 
affected. The addition of exogenous recombinant IL-IO to the RA synovial membrane cultures 
resulted in a two- to threefold decrease in the levels of TNF-ol and IL-1B. IL-8 levels were reduced 
by day 5; however,  IL-6 levels were not affected by exogenous IL-10.  Neutralization of the 
endogenous IL-10 in two out of seven RA synovial membrane cultures resulted in the expression 
of detectable levels of interferon 7 (561-1,050 pg/ml). Taken together, the above findings suggest 
that IL-10 is spontaneously produced in RA and OA and is an important immunoregulatory 
component in the cytokine network of RA, regulating monocyte and in some cases T cell cytokine 
production. 
l~ 
eumatoid arthritis (RA) t is an autoimmune disorder 
that is characterized by a chronic synovitis which often 
leads  to joint  destruction (1).  It  is now established  that 
proinflammatory cytokines such as TNF-o~, IL-1, GM-CSF, 
and IL-6 are all produced by the synovial membrane in RA, 
and are considered to be important participants in the patho- 
physiology of the disease (2-9). However, in addition to these 
proinftammatory cytokines, a compensatory antiinflamma- 
tory response is also observed in RA synovial membranes. 
Thus there is expression of high levels of IL-1 receptor an- 
tagonist (IL-1RA), soluble TNF receptors (of both the 55- 
1 Abbreviations used in this paper: IL-1RA, IL-1 receptor antagonist; OA, 
osteoarthritis, KA, rheumatoid arthritis. 
and 75-kD receptor) and TGF-/5 in the RA synovium (8, 
10-12, and Brennan, E M., manuscript in preparation), which 
suggests that homeostatic mechanisms exist in the rheuma- 
toid joint by which the immune system attempts to contain 
the inflammation and limit joint destruction. 
In contrast to the abundance of monocyte-derived pro- 
inflammatory  cytokines  described  above,  T  cell-derived 
cytokine proteins have often proven difficult to detect in RA 
synovium (13, 14). This is rather paradoxical, since the syno- 
vial membrane-infiltrating T cells appear phenotypically ac- 
tivated (15, 16). However, mRNA for T cell cytokines such 
as IFN-3' and IL-2 has been demonstrated (17), and this sug- 
gests that there may be T cell cytokine inhibitory factors oper- 
ative in the rheumatoid synovium and/or cytokine consump- 
tion. In addition, T cell proliferative responses to mitogens 
are impaired in RA (18-20),  again suggesting the presence 
ofinhibitors. The report that most T cell clones derived from 
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S., unpublished observations), which produce predominantly 
IFN-'y and IL-2 (22),  raises the possibility that one of the 
inhibitory factors present in RA could be IL-10, originally 
defined as "a cytokine synthesis inhibitory factor" capable 
of suppressing cytokine synthesis by murine Thl CD4 + cells 
(23,  24).  However the presence  of IL-10 in RA synovium 
remains to be documented. 
IL-10 is a 35-kD homodimeric cytokine, which is produced 
by human T  cells, B cells, and monocytes (23,  25,  26).  In 
humans, IL-10 exhibits a cytokine synthesis inhibitory ac- 
tivity (CSIF), inhibiting IFN-3,, GM-CSF, IL-4, and IL-5 
production by T cells and can reduce Ag-specific T cell prolifer- 
ation (23,  24).  The latter chiefly involves inhibiting the ca- 
pacity of monocytes to present Ag, a phenomenon mediated 
at least in part through the downregulation of HLA class 
II on monocytes (27). IL-10 has also been shown to have po- 
tent antiinflammatory  properties. IL-10 inhibits the synthesis 
ofproinflammatory  cytokines such as TNF-ot, IL-1, and GM- 
CSF, as well as HLA class II expression by human mono- 
cytes stimulated with LPS (25). 
The reported antiinflammatory  and CSIF properties of 1L-10 
led us to investigate whether IL-10 is produced in RA and 
osteoarthritis (OA), and whether it plays an important im- 
munoregulatory role, regulating monokine and T  cell-de- 
rived cytokine production. Here we describe the presence of 
IL-10 mRNA and protein in RA and OA synovial mem- 
brane biopsies.  We also report spontaneous IL-10 produc- 
tion in RA and OA synovial membrane cultures, and evi- 
dence that  suggests  that it  has  an  important  role in  the 
synovium as a regulator of production of the inflammatory 
cytokines TNF-ot and IL-1.  IL-10 may thus have a possible 
role in new therapeutic approaches to inflammatory arthritis. 
Materials and Methods 
Patient Samples and Cell Cultures.  11 patients with RA fulfilling 
the revised American Rheumatology Association (AIL/i) criteria 
(28), and 17 patients with OA, all of  whom underwent  joint replace- 
ment surgery, were included in this study. Synovial  membrane cell 
suspension cultures were prepared by collagenase  and DNase diges- 
tion of membranes as previously described (12). In brief, synovial 
membrane tissue was digested in ILPMI 1640 containing 5% FCS 
(Flow,  High  Wycombe, UK),  1  rag/m1 collagenase type  A 
(Boehringer, Mannheim, Germany), and 0.15 mg/ml DNase type 
1 (Sigma Chemical Co., Poole, UK) for 2 h at 37~  After incuba- 
tion, the tissue was pipetted through a 200-#m 2 nylon mesh into 
a sterile beaker. Cells were then washed three times with ILPMI 
1640 plus 5%  FCS. Synovial membrane cells were cultured at 
10+/ml/well in RPMI plus 5%/FCS in 24-well plates (Nunc, Ux- 
bridge, UK) at 37  ~ in a 5% CO2 incubator, and supernatants were 
harvested at 24, 72, and 120 h. Synovial membrane cell cultures 
were treated with 2/zg/ml of neutralizing rat monoclonal anti-ID 
10 antibody 9D7, rat isotype control antibody GLl13, or 10 ng/ml 
rlL-10. Supernatants were frozen at -20~  until assayed.  Synovial 
fluid exudates from nine RA and three OA patients were aspirated 
during needle biopsy, cells were spun down at 1,000 rpm, and su- 
pernatants were assayed at a 1:2 dilution in PBS in the II+-10 and 
isotype control ELISA. Synovial fluids were also assayed  for IL-IO 
after treatment with hyaluronidase. In brief, synovial fluids were 
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incubated with 4 U/m1 hyaluronidase (Sigma Chemical Co.) for 
30 rain at 37~  (11), after centrifugation at 2,200 rpm for 12 min. 
Supernatants were then assayed in the ID10 and isotype control 
ELISA. All media and reagents were found to have <0.1 EU/ml 
endotoxin contamination by the chromogenic Limulus Amoebo- 
cyte Lysate  assay (BioWhittaker, Walkersville, MD). The only ex- 
ception was the rat monoclonal anti-IL-10 neutralizing antibody 
9D7 which at the concentration of 2 #g/ml used had 0.13 EU/ml 
endotoxin contamination. This led to the inculsion of 10/~g/ml 
Polymyxin B (Sigma Chemical Co.) controls in three of the cul- 
tures, to exclude the effect of endotoxin. In three other cultures, 
the endotoxin-free  rat monoclonal neutralizing anti-IL-10  antibody 
12G8 at 2 #g/ml was also included as another control for the 9D7 
antibody. 
ELISAs and Antibodies.  Recombinant human II+-10, rat mono- 
clonal anti-IIA0 neutralizing IgG1 antibody 9D7, rat monoclonal 
isotype control IgG1 antibody GLl13, rat monoclonal  neutralizing 
IgG2 antibody 12G8, and specific ELISA for human/viral IL-10, 
were generously  provided  by Drs. K. Moore andJ. Abrams (DNAX, 
Palo Alto, CA). The sensitivity of the IL-IO ELISA  was 100 pg/ml. 
A control ELISA  which differed  from the IL-10  ELISA  only in that 
the coating antibody  was the nonspecific  isotype  control mAb GLl13 
was also used to exclude  the effect of RF. A specific  TNF-a ELISA 
was kindly provided by Dr. W. Buurman (University of Limburg, 
Maastricht, The Netherlands). The IL-1B  ELISA  was commercially 
purchased (R & D Systems, Inc., Minneapolis, MN).  The IL-6, 
II+-8, and IFN-'y ELISAs  were gifts from Drs. F. di Padova (Sandoz 
Pharma AG, Basel, Switzerland), W. Lee Wong (Genentech Inc., 
S. San Francisco, CA), and D. Novick (Weismann Institute, Re- 
hovot, Israel), respectively. Neutralizing anti-TNF~ and anti-ID 
13 mouse mAbs A2 and IL-1RA were kind gifts from Dr. P. Dad- 
dona  (Centocor, Malvern, PA)  and  Dr.  D.  Tracey (Upjohn, 
Kalamazoo, MI). Apart from the ILl0 ELISA, the neutralizing 
anti-IL-10 antibodies did not interfere in any of the above ELISA 
assays. 
Immunohistology.  Synovial  membrane biopsies of patients with 
RA (n =  5) and OA (n  =  4) were taken at arthroscopy of knee 
joints and snapffozen in iso-pentane cooled on liquid nitrogen. 
Normal synovial  membrane specimens (n = 3) were obtained from 
the knee joint of patients undergoing amputation for osteogenic 
sarcoma at a site distant for the knee joint. The synovial mem- 
branes were sectioned at 6 #m and immunohistochemical staining 
was performed as described  previously  (8). The sections were fixed 
in acetone at  -20~  and blocked with 20% normal goat serum, 
then incubated with 10/~g/ml rat monodonal IgG1 anti-IL-10  an- 
tibody 2A5 (DNAX) overnight at 4~  Binding was detected by 
incubating the sections twice with goat anti-rat Ig alkaline  phos- 
phatase conjugate (Dako, High Wycombe, UK) for 30 rain at room 
temperature, followed by alkaline phosphatase-antialkaline phos- 
phatase (APAAP) complexes (Dako) for 30 min at room tempera- 
ture and visualized  with Fast red (4-chloro-2-methylbenzenediazo- 
nium  zinc  chloride).  Normal  rat  monoclonal  IgG1 (Serotec, 
Kidlington, UK) at the equivalent protein concentration served 
as a negative control. The staining of the 2A5 anti-Ibl0 antibody 
was abrogated  by preincubating  the antibody with 10 #g/ml human 
rIL-10 for 2 h at 37~  before application to the sections. For double 
immunofluorescence  staining, the anti-IL-10  antibody was detected 
with a biotinylated donkey anti-rat IgG with minimum cross- 
reactivity to  mouse serum proteins (Jackson Immunoresearch, 
Luton, UK) and followed  by streptavidin-fluorescein  (Amersham, 
Aylesbury,  UK). Mouse anti-human CD3, CD20, and CD68 mAbs 
(Dako) were detected  with Texas  red--conjugated  donkey  anti-mouse 
IgG with minimum cross-reactivity  with rat serum  proteins (Jackson 
Immunoresearch). 
Immunoregulatory  Role of IL-10 in Rheumatoid Arthritis PCR  Amplification and  Northern Blot.  RNA  was  extracted 
directly  from  synovial  membrane  tissues  by  the  guanidinium 
isothiocyanate method (29).  To synthesize cDNA,  1/zg of total 
RNA was incubated with 2/xg oligo (dt)02_ls) primers (Pharmacia, 
Milton Keynes, UK), 5 ng BSA, 0.5 mM dNTPs, 10 mM DTT, 
10/zl xl0 RT buffer (Y00146; GIBCO BILL, Uxbridge, UK), and 
20 U murine Moloney leukemia virus reverse transcriptase (GIBCO 
BILL) (30). PCIL reactions were performed using 5/A of this cDNA 
in the presence of 50 mM KC1, 10 mM Tris, pH 8.3,  1.5 mM 
MgC12, gelatin (0.001%), 0.2 mM dNTPs, 1 #M of each primer, 
and 1.25 U Taq Polymerase (Perkin Elmer Cetus, Beaconsfield, UK) 
in a total of 50/A. PCR analysis was performed using two human 
IL-10 27-mer primers, spanning nucleotides 323-349 (sense strand) 
and 648-674 (antisense strand) (23). These primers do not amplify 
the viral homologue of I1r  BCILF1. Samples were overlaid with 
50 #1 of  light mineral oil (Sigma Chemical Co.) and were incubated 
at 94~  for 1 min, 55~  for 1 min, and 72~  for 2.5 min. This 
cycle was repeated 35 times using a DNA thermal cycler (Perkin 
Elmer  Cetus)  (31).  10  /xl PCIL products  were electrophoresed 
through a 6% polyacrylamide gel and visualized by ethidium bro- 
mide staining.  10/A amplified DNA was digested with 1 U HaelII 
restriction enzyme (New England Biolabs, Bishop's Stortford, UK) 
for 1 h  at 37~  and yielded the expected 123- and 229-bp size 
products. 
For Northern blot analysis, total ILNA was extracted as above 
from single cell suspension cultures of two RA synovial membranes 
which were treated for 24 h with either nothing, 2/~g/ml anti-Ib 
10 neutralizing rat mAb 9D7, 2/~g/ml isotype control rat mAb 
GLll3, or 10 ng/ml rill0.  Total RNA was  size fractionated by 
electrophoresis after denaturation with glyoxal and DMSO and then 
transferred to a Hybond-N nylon membrane (Amersham). After 
transfer, the membrane was baked for 2 h at 80~  Before hybrid- 
ization, glyoxal was removed from RNA by washing the filter with 
20 mM Tris-HC1,  pH 8.0,  at 65~  The membrane was  prehy- 
bridized in prehybridization buffer: 6 x  SSC (1 x  SSC  =  150 mM 
NaC1,  15 mM Na Citrate, pH 7.0),  5 x  Denhardt's reagent (1 x 
Denhardt's  =  0.05%  Ficoll 400,  0.05%  polyvinylpyrrolidone, 
0.05% BSA), 0.5% SDS, 100 #g/ml salmon sperm DNA (Sigma 
Chemical Co.), and 50% formamide (BDH, Poole,  UK) for 2 h 
at 42~  Membranes were hybridized overnight at 42~  with a 
cDNA probe to TNF-ot (kind gift H. M. Shepard,  Genentech) la- 
beled with ~_[32p] dCTP (Amersham). Membranes were washed 
with 2x  SSC and 0.5% SDS at room temperature, 2x  SSC and 
0.1% SDS at room temperature, 0.1 x  SSC, and 0.5% SDS at 37~ 
and 0.1x  SSC and 0.5% SDS at 65~  Membranes were then ex- 
posed to Hyperfilm-MP (Amersham) at - 70~  The TNF-c~ probe 
was stripped from membranes by immersing membranes in 1 mM 
Tris-HC1,  pH 8.0,  1 mM EDTA, pH 8.0,  and 0.1x  Denhardt's 
reagent for 2 h at 75~  Membranes were prehybridized and then 
hybridized with a probe to the 7B6 housekeeping gene (32). Au- 
toradiographs were scanned on a dual wavelength TLC scanner C8- 
930 (Shimadzu,  Kyoto, Japan). 
Statistics.  Results were analyzed with Wilcoxon's signed rank 
test. 
Results 
IL-IO Is Produced by RA and OA Synovial Membranes.  IL-10 
was produced by all 11 RA and 17 OA synovial membrane 
cultures  tested.  The IL-10 levels were measured by specific 
ELISA, and at 24 h ranged from 358 to 5,501 pg/ml for RA 
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Figure  1.  ILl0 protein and mtLNA is expressed  in RA (O) and OA 
(A)  synovial membranes. (A) Ibl0 is produced spontaneously by RA 
(n =  11) and OA (n =  17) synovial  membrane cultures, assayed  by ELISA 
at 24 h. (B) PCR of human IF10 and 3-actin amplified  from cDNA made 
by reverse  transcription  of total RNA extracted  directly  from synovial  tissue. 
Synovium  from five  RA patients (lanes I-5), synovium from five  OA pa- 
tients  (lanes 6-10), unstimulated  normal  PBMs (lane 11), and  anti- 
CD3-stimulated normal PBMs (lane 12). 
1519  Katsikis  et al. Figure 2.  Immunohistological  staining for Ibl0 in RA synovial  membranes. (.-4) Ibl0 staining in the synovial  membrane lining layer. (B) Preincuba- 
tion of anti-IL-10 antibody with rlL-10 results in abrogation of staining. (C) Lack of staining with isotype  control rat mAb. (D) Ibl0 staining in the 
RA synovial  membrane  mononuclear  aggregates. (E) No II:10 staining detected  in normal synovial  tissue. (F and G) IL-10  and monocyte  immunofluores- 
cence double staining in RA synovial membrane lining layer. (F) Ibl0 staining (9I)7 anti-IL-10 rat mAb, followed  by biotinylated donkey anti-rat 
IgG and streptavidin-fluorescein).  (G) Monocyte/macrophage  staining (anti-human CD68 mouse  mAb, followed  by Texas  red-conjugated  donkey  anti-mouse 
IgG antibody). (H and/) IL-10  and T cell immunofluorescence  double staining in RA synovial  membrane mononuclear aggregate. (/-/) IL-10  staining 
(9D7 anti-Ibl0 rat mAb, followed  by biotinylated  donkey  anti-rat IgG and streptavidin-fluorescein). (/) T cell staining (anti-human CD3 mouse mAb, 
followed by Texas red-conjugated donkey anti-mouse IgG antibody). (Arrows)  Individual cells that double stain for IL-10 and CD3. 
and 310 to 3,390 pg/ml  for OA cultures  (Fig.  1 A).  IL-10 
levels remained detectable up to 5 d in culture. No difference 
in IL-10 was observed between synovial cultures of RA and 
OA patients.  IL-10 was not detected (<100 pg/ml) in either 
PBS-diluted or hyaluronidase-treated  synovial fluids of nine 
RA and  three OA patients  (data not  shown).  All samples 
were tested in the control ELISA (isotype-matched, antibody- 
coated plate) to exclude RFs and showed no binding.  IL-IO 
mRNA was demonstrated by PCR amplification of reverse 
transcribed cDNA in five out of five RA patients,  and four 
out of five OA patients  (Fig.  1 B).  IL-10 was also detected 
by immunohistological staining of synovial membrane tissue 
in all five RA and four OA membranes examined.  Cell staining 
with IL-IO was found in the synovial membrane limiting layer 
and the mononuclear aggregates. (Fig. 2). This staining was 
shown to be specific  for IL-10 since it could be abrogated 
by preincubation of 2A5 staining antibody with recombinant 
human IL-10, and the isotype control mAb yielded no staining. 
(Fig.  2).  There was no IL-10 staining  in the three normal 
synovial membranes examined (Fig.  2). By immunofluores- 
cence double staining,  IL-10 was shown to be produced by 
monocytes in the lining layer and T cells in the lymphocytic 
aggregates  (Fig.  2). 
Regulatory Role of  lL-lO in Proinflammatory  Cytokine  Produc- 
tion in Rheumatoid  Synovial  Membranes.  Blocking IL-IO with 
the  neutralizing  rat  monoclonal  anti-IL-10  antibody  9D7 
resulted in an increase in the proinflammatory cytokines pro- 
duced by the rheumatoid synovial membrane cultures. After 
24 h  in culture,  the TNF-o~ and IL-1B levels  measured by 
specific ELISAs increased to 208  _+  16%  and  198  +  25% 
(x  -+  SEM) of the control levels respectively (p <0.01  and 
p  <0.01).  The effect of anti-IL-10  was sustained  up to day 
5,  when  TNF-c~ was increased to 322  _+  91%  and IL-1B 
to 235  +  65% of control levels. In contrast, blocking IL-10 
had no significant effect on IL-6 and IL-8 production (Table 
1, Figs.  3 and 4). Northern blot analysis  was performed on 
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two cultures with anti-IL-10 resulted in a twofold increase 
in TNF-ol protein produced, however the TNF-o~ mKNA 
levels did not change (data not shown). Addition of 10 #g/ml 
polymyxin  B to three RA synovial  membrane cultures treated 
with the 9D7 antibody,  and treatment of three RA mem- 
branes with the endotoxin-ffee  neutralizing anti-IL-10 anti- 
body 12G8 gave  identical results to the 9D7 treatment (data 
not shown). The rat isotype control mAb GLl13 had no effect 
on TNF-ol and IL-I~ produced by the synovial membranes 
(Fig. 3). It was of interest,  in view of the original function 
of IL-10 described (cytokine synthesis inhibition)  that anti- 
IL-10 treatment resulted in detectable levels of IFN-y in two 
RA membranes (561 and 1,050 pg/ml, respectively) out of 
seven 24-h cultures that were assayed.  In contrast, in the control 
cultures, or isotype control antibody-treated cultures, IFN-'y 
levels were undetectable  (<100 pg/ml). 
Exogenous Addition of lL-lO to Synovial Membrane Cultures 
Inhibits Proinflammatory Cytokine Production.  The levels of 
IL-10 produced by the synovium membrane cultures were 
all, with the exception of one (5 ng/ml), <2 ng/ml. We there- 
fore investigated whether the IL-10/IL-10  receptor system 
in these cultures was saturated, and whether addition of ex- 
ogenous IL-10 would have any effect on monokine produc- 
tion. Addition of 10 ng/ml of IL-10 resulted in marked de- 
crease in cytokine production. At 24 h, TNF-o~ was reduced 
to 49  _+  6%  and IL-13 to 64  _+  11% of control (p <0.01 
andp -  0.02, respectively), and this reduction was even more 
marked by day 5 (TNF-ol to 42  +  9% and IL-13 to 51  -+ 
9%  of control) (Table 2, Figs. 3 and 4). Exogenous IL-10 
did not reduce TNF-ot mR.NA levels at 24 h in two RA 
cultures in which the IL-10 protein levels were reduced by 
twofold (data not shown). IL-6 levels were not affected by 
1521  I~tsikis  et al. Table  1.  Effect of Anti-IL-lO  Treatment on Cytokine Production by Synovial Membrane Cultures 
TNF-ot  IL-1B  IL-6  IL-8 
O'S/toO  O'S/toO  (ng  /mO  (ng  /mt) 
Control  1,161  +  370 (n  =  10)*  1,549  _+  659 (n  =  9)  151  _+  61  (n  =  7)  242  _+  75  (n  =  7) 
Day 1  Anti-IL-10  2,236  •  649  2,899  _+  991  160  +  61  271  +  76 
Isotype control  1,168  +  380  1,542  +  660  142  _+  56  258  •  79 
Control  301  •  133  (n  =  8)  1,630_+  1,159(n  =  6)  264  +  83  (n  =  7)  473  _+  148  (n  =  7) 
Day 3  Anti-IL-10  1,025  +  505  2,513  _+  1,665  280  _+  80  514  +  142 
Isotype control  295  +  134  1,761  •  1,284  276  +  83  510  +_  161 
Control  185  +  100  (n  =  6)  472  _+  182  (n  =  5)  269  _+  66  (n  =  6)  438_+  100  (n  =  6) 
Day 5  Anti-IL-10  1,024  •  781  1,170  +  516  272  •  59  535  _+  121 
Isotype control  173  •  92  381  •  210  282  +  73  419  +  95 
* Mean  _+ SE, n  =  number of cultures. 
exogenous IL-IO addition to the RA cultures. IL-8 produc- 
tion was only affected by day 5, reduced to 68  +  7% of con- 
trol (p  =  0.05).  (Table  2,  Figs.  3  and 4). 
Blocking of TNF-cr and IL-1 Downregulates IL-IO Production 
by the Synovial Membrane Cultures.  IL-1RA (10 #g/ml) con- 
sistently inhibited IL-IO production,  IL-10 was reduced at 
24 h  to 68  _+  8%,  at day 3  to 57  +  7%,  and at day 5  to 
50  +  13% of control.  (data not shown). Anti-TNF-c~ neu- 
tralizing mAb antibody A2 (5 #g/ml)  also resulted in a de- 
crease, albeit lesser, in IL-IO levels produced by the synovial 
membrane cultures at 24 h to 80  _+  8%  (p <0.05),  at day 
3 to 76  _+  8%,  and at day 5 to 75  +  11% of control (data 
not shown). However, anti-TNF-ce and IL-1RA, when used 
in combination, showed no additive or synergistic effect (data 
not shown), suggesting that TNF-c~ and IL-1 regulate IL-10 
levels by a common pathway, 
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Figure 3.  RA  synovial  mem- 
brane cultures: effect of neutralizing 
endogenously produced II.-10  and of 
the  addition of exogenous  1I.-10. 
Representative  experiment showing 
TNF-ce, IL-1B, IL-6, and IL-8 levels 
produced  by RA  synovial mem- 
brane  culture  SM1376.  Synovial 
membrane culture  was treated with 
either neutralizing rat monoclonal 
anti-ILl0 antibody 9D7 (2 #g/ml), 
isotype-matched control rat mono- 
clonal GLl13, or 10 ng/ml ofrlbl0 
for  24,  72,  and  120  h.  (Similar 
studies have  been performed on 5-10 
membranes;  see Table 1).  (-K]-) 
Control; (-0-) anti-IL-10;  (-O--) 
isotype control;  (-I-)  IL-10. Figure 4.  Neutralization of spontaneously produced IL-10  and addition 
of exogenous II.,10 in RA synovial membrane cultures. Pooled data from 
5-10 RA synovial membrane cultures. (A) Neutralization of endogenous 
Ibl0 with the 9D7 neutralizing rat monodonal anti-IL-10 antibody (2 
#g/ml) results in increased levels of TNF-c~ and IL-1B, but not Ib6 and 
Ib8. (B) Exogenous rlL-10 (10 ng/ml) decreases TNF-c~ and IL-1/~  levels 
in RA cultures.  (Dashed lines) 100% of control untreated cultures. 
Discussion 
As  judged by quantity, the major participants in the cytokine 
network of rheumatoid synovitis are the monocyte and fibro- 
blast-derived  inflammatory cytokines,  including  TNF-ot, 
IL-1/3, IL-6, GM-CSF, and IL-8. These are produced sport- 
taneously in the diseased synovial membrane, and are consid- 
ered to play an important role in the pathophysiology of the 
chronic synovitis (33-35). Recently, TGF-B and cytokine in- 
hibitors such as IL-1RA and soluble TNF receptors (both 
p55 and p75 ffNFK) have also been found in synovial fluids 
and shown to be produced by synovial membrane cultures 
from RA patients (8, 10-12,  and Brennan, F. M., manuscript 
in preparation), and presumably represent a homeostatic at- 
tempt to contain the inflammation. The recent description 
of the potent antiinflammatory properties of IL-10 (23,  25) 
prompted us to investigate whether IL-10 was produced by 
the synovial membrane in RA, and if it played a regulatory 
role in the cytokine network in synovitis. 
In this study, IL-10 was detected at both the mRNA and 
protein level in RA synovial membranes. PCR of reverse tran- 
scribed total RNA extracted directly from synovial membrane 
tissue showed that human IL-10 mRNA is present in these 
membranes. Biologically significant quantities of IL-10 were 
spontaneously produced in cell suspension cultures of RA 
synovial membranes, and persisted for the 5-d duration of 
the synovial cultures. IL-10 protein was also demonstrated 
in RA and OA synovial tissues  by immunohistology, but 
not in the normal synovium. IL-10 immunostaining showed 
that monocytes in the synovial membrane lining layer, and 
T cells in the mononuclear aggregates stained for IL-10. IL-IO 
however could not be detected in RA and OA synovial fluids 
by ELISA. 
The IL-10 produced spontaneously by the RA cultures was 
shown by neutralization experiments to play an important 
regulatory role in KA in the synovial membrane cultures. 
Blocking IL-10 in these cultures with a neutralizing mAb 
resulted in a two- to threefold increase in the production of 
TNF-cz and IL-1/3. This result probably has pathogenetic con- 
sequences, as TNF-cx and IL-1/3 are implicated in the pathology 
of KA, since they can both induce bone resorption and carti- 
lage destruction,  and can stimulate PGE2 release and col- 
lagenase production (33),  and blocking TNF-o~ in RA pa- 
tients with a high affinity neutralizing chimeric anti-TNF-cz 
antibody has been shown to result in clinical benefit (36). 
The suppression of these cytokines by IL-10 thus appears to 
Table  2.  Effect of lL-10  Treatment on  Cytokine  Production by Synovial Membrane Cultures 
TNF-o~  IL-1/~  IL-6  IL-8 
Day 1  Control  1,145  +  418  (n  =  9)*  1,708  -+  850  (n  =  7)  135  •  63  (n  =  7)  227  +  77  (n  =  7) 
IL-10  563  •  210  1,098  +_  725  125  +  56  200  +  69 
Day 3  Control  301  •  133 (n  =  8)  1,563  +  1,168 (n  =  6)  248  _+  86 (n  =  7)  479  •  147 (n  =  7) 
IL-10  106  •  36  1,317  •  1,041  242  •  83  449  •  135 
Day 5  Control  185  _+  100 (n  =  6)  407  _+  147 (n  =  5)  241  +_ 65  (n  =  6)  438  •  100 (n  =  6) 
IL-IO  55  •  24  204  •  89  231  -+ 60  308  •  76 
* Mean  +_  SE, n  =  number of cultures. 
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mation. The observation that IL-10 upregulates the produc- 
tion of IL-1RA and soluble TNF receptors by human mono- 
cytes (Joyce, D., D. Gibbons, P. Green, M. Feldmann, and 
F. M. Brennan, manuscript submitted for publication) also 
supports this concept. There is thus increasing evidence that 
in RA, IL-10, IL-1RA, and soluble TNF receptors are con- 
stituents of an important antiinflammatory response.  It is 
noteworthy that blocking IL-IO in the RA cultures had no 
effect on the IL-6 and IL-8 levels, which was somewhat un- 
expected, since IL-IO inhibits both IL-6 and IL-8 production 
by LPS-activated  human monocytes (25). A possible expla- 
nation may lie in the fact that in P,A synovial membrane 
cultures another important source of these two cytokines are 
fibroblasts  and endothelial cells (6, 37, 38).  In our labora- 
tory, IL-10 has failed to have any significant  effect on syno- 
vial fibroblast  IL-6, IL-8 or PGE2 production (Butler,  D., 
F. M. Brennan, and M. Feldmann, unpublished observation). 
Exogenous addition of IL-IO to RA synovial membrane 
cultures resulted in a two- to threefold decrease of TNF-cz 
and IL-13 production, noticeable by 24 h, the first assay point. 
However, IL-8 was only affected by day 5 in culture, and this 
may reflect an indirect effect oflL-10 on IL-8 expression sub- 
sequent to downregulating IL-1  and TNF. As mentioned 
above,  IL-IO  induces soluble TNF receptors and IL-1RA 
production by human monocytes, and thus the net effect of 
IL-IO on the biological activity of TNF-c~ and IL-1 in the 
synovial membranes would be expected to be even greater 
than  that  resulting exclusively  from downmodulation of 
TNF-(x and IL-1 protein levels. The above results also indi- 
cate that the IL-IO/IL-IO receptor system is not saturated 
in these RA cultures. This implies that there is a "relative 
deficit" in IL-IO production in RA, which suggests the pos- 
sibility of a novel therapeutic strategy for RA by augmenting 
this interaction. 
TGF-3 and IL-4 are both cytokines with potent antiinflam- 
m atory properties (39, 40),  and therefore could possibility 
be antiinflammatory agents of use in RA. However in ex- 
perimental animal models of arthritis, TGF-3 treatment has 
yielded conflicting results (41, 42). In a report using RA sy- 
novial membrane explants cultured for 10 d, IL-4 was shown 
to inhibit IL-6, IL-13, and TNF-cz (43). However, the failure 
to characterize  the cellular  sources of cytokine production 
during the 10-d period of culture limits the interpretation 
of these results.  In contrast to IL-IO, TGF-3 and IL-4 have 
both failed in our hands to inhibit inflammatory cytokine 
production in RA synovial membrane cell suspension cul- 
tures (12, 44). Suppression of LPS induced PBMC monokine 
production by TGF-~/, and IL-4 depends on the pretreatment 
of these cells with these cytokines (12, 45).  Thus, the in- 
ability of TGF-3 and IL-4 to have any effect in RA cultures 
could be due to the chronic activation of monocytes. IL-IO 
is therefore the first cytokine shown to have an inhibitory 
effect on RA synovial membrane culture cytokine synthesis. 
IL-1 and TNF-cz were found to participate in the regula- 
tion of IL-10 production by the RA synovial membrane. This 
is in concordance with our recent data which indicate that 
IL-1, and to a lesser extent TNF-cz, are both involved in the 
regulation of IL-10 production by LPS-activated  human mono- 
cytes (Katsikis, P., unpublished observation). In the RA cul- 
tures it is possible that the anti-TNF-cz-mediated downregu- 
lation of IL-IO may be the indirect result of its inhibition 
of IL-1 (46).  This possibility is also supported by the lack 
of an additive or synergistic effect of anti-TNF-oe  with IL- 
1RA, when used in combination in the RA synovial mem- 
brane cultures. 
An interesting paradox in the studies of the pathogenesis 
of RA which has been highlighted by Firestein et al.  (13, 
14), has been the failure to detect abundant T cell cytokines, 
although activated T cells as judged by cell surface markers 
are present in the synovium (15, 16). However, we have pre- 
viously reported the detection of T cell cytokine mRNA (IL-2 
and IFN-'y) in the RA synovium (17), suggesting that an 
inhibitor may be present and responsible for the low protein 
detection. Cloning of these T cells has revealed a Thl cytokine 
profile (21, and Cohen, S., unpublished observations), making 
IL-10 a candidate for such an inhibitor, since IL-IO has been 
reported to be a potent inhibitor ofThl cytokine production 
(23, 24, 27). Preliminary data shows that in two out of seven 
RA membranes studied, IFN-7 which was undetectable in 
control cultures, could be measured at significant concentra- 
tions after the neutralization of endogenous IL-IO. Clearly, 
more rheumatoid membranes need to be studied, but the data 
already obtained suggest that IL-IO may be the (or one of 
the) factor responsible for the "elusiveness" of T cell-derived 
cytokines. T cell proliferative responses are also impaired in 
RA (18-20).  TGF-3 has been implicated as a major but not 
the sole immunosuppressive  factor in RA synovial fluids (20). 
The direct inhibitory effect of IL-IO on T cell proliferation 
and IL-2 production (48, 49), and its indirect effect via APCs 
(24, 27, 50) raises the possibility that IL-IO also contributes 
to the low T cell proliferative responses in RA. This, how- 
ever, remains to be established. 
The data reported here indicate that in RA, IL-10 plays 
an important role in the cytokine network, by inhibiting the 
cytokine production of both monocytes and T cells. In the 
RA synovium, IL-IO regulates the production of TNF-oJIL-1 
and vice-versa. In rheumatoid synovium, IL-10 and IFN-y 
may be reciprocally regulated also, IL-IO possibly inhibiting 
IFN-y production, and IFN-y regulating IL-10 (51). Although 
most of the properties of IL-IO suggest that it has a negative 
regulatory role, recent observations indicate that IL-IO may 
not be a general inhibitor of immune responses, since it can 
stimulate monocyte expression of the Fc receptor for mono- 
meric IgG, FcyRI (CD64), and enhance antibody-dependent 
cellular cytotoxicity (52).  Another recent report (53) indi- 
cates that IL-IO might be a potent recruitment signal (or in- 
ducer of) for leukocyte migration in vivo. Thus, animal studies 
are needed to establish whether IL-10 treatment in vivo may 
modulate the arthritis. Recent reports of IL-IO treatment of 
experimental endotoxemia in mice have shown that in vivo 
administration of IL-IO significantly reduces TNF-o~ levels 
and mortality (54,  55),  suggesting that IL-IO could be an 
effective antiinflammatory in vivo. 
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and biopsies.  Monokine-derived proinflammatory cytokines 
such as TNF-ot, IL-1, and GM-CSF (9, 46) and antiinflamma- 
tory products such as soluble TNF receptors  and IL-1RA 
(7, 8, 10, 11) are all produced by the OA synovial membrane 
macrophage. The role of proinflammatory cytokines in the 
pathogenesis of osteoarthritis, which is considered a nonau- 
toimmune but inflammatory disease, has not yet been studied 
in detail. It seems that in OA as in R.A, IL-10 may be pro- 
duced alongside soluble TNF receptors and IL-1RA to limit 
the deleterious effect of proinflammatory cytokines. 
In this study we have shown that both mRNA and pro- 
tein for IL-10 are present in the RA and OA synovium, and 
that IL-IO is an important participant in the cytokine net- 
work of the rheumatoid synovial membrane, playing an im- 
munoregulatory role in inflammatory and possibly T  cell 
cytokine production. Reciprocally,  IL-10 itself is regulated 
by IL-1 and TNF-ot, thus IL-10 appears to be an important 
component of the complex cytokine network of rheumatoid 
synovitis. Finally, exogenous IL-10 was shown to inhibit both 
TNF-ot and IL-1/~ production by RA synovial membrane 
cultures. These findings raise the possibility of new therapeutic 
strategies  for the treatment rheumatoid arthritis. 
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